Browse News
Filter News
Found 260 articles
-
Vaxart Appoints W. Mark Watson to its Board of Directors
8/8/2022
Vaxart, Inc. (NASDAQ: VXRT) today announced that W. Mark Watson was appointed to the Company’s Board of Directors, effective August 4, 2022.
-
Vaxart Provides Business Update and Reports Second Quarter 2022 Financial Results
8/8/2022
In its business update today for the second quarter of 2022, Vaxart, Inc. (NASDAQ: VXRT) said it has begun working on vaccine candidate constructs that directly target new omicron variants of concern and is preparing to release top-line data in the third quarter of 2022 from its Phase II COVID-19 testing of a Wuhan strain vaccine construct.
-
Vaxart Stockholders Approve Proxy Proposals 2, 3 and 4
8/5/2022
Vaxart, Inc. announced that at its reconvened Annual Meeting of Stockholders on August 4, its stockholders had voted to approve Proposals 2, 3 and 4.
-
Vaxart to Host Second Quarter 2022 Business Update and Financial Results Conference Call on August 8
7/28/2022
Vaxart, Inc. announced it will provide a business update and report financial results for the second quarter ended June 30, 2022 after the market close on Monday, August 8, 2022.
-
Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET
7/27/2022
Vaxart, Inc. (Nasdaq: VXRT) today urged its stockholders of record on April 11, 2022, to vote on its proxy if they have not yet done so and encouraged them to vote yes on all Proxy Proposals, including Proxy Proposal #2.
-
Researchers evaluate just how well therapeutic antibodies and antivirals work against Omicron, Vaxart's oral vaccine shows early promise and hypertension doubles the risk of hospitalization.
-
Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive
7/20/2022
Vaxart (NASDAQ: VXRT) today reported additional phase 1 clinical data published on medRixv.org, indicating that its Spike/Nucleocapsid (S+N) oral tablet COVID-19 vaccine induced long-lasting mucosal IgA antibodies against SARS-CoV-2 the virus that causes COVID-19, and all tested coronaviruses.
-
GV20 Therapeutics Announces Appointment of Three Advisers
7/20/2022
GV20 Therapeutics , a biopharmaceutical company using cutting-edge genomics and artificial intelligence approaches to discover next-generation cancer therapeutics, announced the appointment of three key advisers as it prepares to advance its first drug candidate into the clinic.
-
Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022
7/14/2022
Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. Rebecca Flitter, Senior Scientist, each will present data from the company’s COVID-19 oral tablet vaccine development program at the International Congress of Mucosal Immunology 2022, which is being held in Seattle July 16 to 20, 2022.
-
Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ET
7/1/2022
Vaxart, Inc. urges its stockholders of record on April 11, 2022, to vote on its proxy if they have not yet done so.
-
Vaxart Announces Agreement with hVIVO to Develop World’s First Human Omicron Challenge Model
6/30/2022
Vaxart, Inc. (Nasdaq: VXRT) today announced an agreement with hVIVO Services Limited, a subsidiary of Open Orphan plc (AIM: ORPH) under which hVIVO will conduct a characterization study and, if successful, develop a human challenge model based on the Omicron variant of SARS-CoV-2.
-
Vaxart to Host Investor Q&A Webcast
6/16/2022
Vaxart, Inc. announced that it will host a question-and-answer webcast with investors and analysts on Wednesday, June 22, 2022, at 1:00 p.m. Eastern Time.
-
Vaxart Announces Adjournment of Annual Meeting of Stockholders - June 08, 2022
6/8/2022
Vaxart, Inc. announced that its 2022 annual meeting of stockholders has been adjourned to Wednesday, July 6, 2022 at 9:30 a.m. Pacific Time with respect to all proposals described in Vaxart’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 28, 2022.
-
It was a busy, busy week for clinical trial news and updates, largely driven by the annual ASCO meeting taking place June 3-7 in Chicago.
-
New Preclinical Data Demonstrate Two of Vaxart’s COVID-19 Vaccine Candidates Protect Against Omicron
6/3/2022
Vaxart, Inc. (NASDAQ: VXRT) today reported positive preliminary preclinical data demonstrating that two COVID-19 vaccine candidates targeting either the SARS-CoV-2 spike (S) protein for Wuhan or S protein for Omicron protected hamsters when challenged with the Omicron BA.1 variant.
-
Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults
6/2/2022
Vaxart (NASDAQ: VXRT) today reported positive preliminary data from its recently completed Phase 1b trial of its oral vaccine candidate in subjects aged 55 – 80 years (NCT04854746).
-
Vaxart to Participate at the Jefferies Global Healthcare Conference
6/2/2022
Vaxart, Inc. announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. James Cummings, Chief Medical Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday, June 9, 2022 at 10:30 a.m. ET.
-
ChemoCentryx Announces Changes to its Board of Directors
5/31/2022
ChemoCentryx, Inc., announced changes to the composition of its Board of Directors.
-
Altesa BioSciences to Initiate Clinical Trials of Promising Antiviral
5/26/2022
Altesa BioSciences, Inc. (Altesa), a clinical-stage biopharmaceutical company developing and commercializing novel antiviral drugs against common respiratory viruses and global viral threats, has U.S. Food & Drug Administration approval to proceed with a clinical study of a promising antiviral treatment, vapendavir.
-
Altesa BioSciences Recognizes Co-Founder and Partner for Major NIH Research Grant to Discover New Antiviral Drugs
5/25/2022
Altesa BioSciences, Inc., today recognized George Painter, PhD, a co-founder of Altesa and chairman of the Altesa Scientific Advisory Board for earning a major research grant from the National Institute of Allergy and Infections Diseases (NIAID), part of the National Institutes of Health.